MDXG - MiMedx Group, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

MiMedx Group, Inc.

1775 West Oak Commons Court, NE
Marietta, GA 30062
United States
770-651-9100
http://www.mimedx.com

SectorHealthcare
IndustryMedical Devices
Full Time Employees690

Key Executives

NameTitlePayExercisedYear Born
Mr. Scott M. TurnerSr. VP of Operations & Procurement421.27kN/A1966
Mr. Timothy R. WrightCEO & DirectorN/AN/A1958
Mr. Peter Martin Carlson CPAExec. VP & CFON/AN/A1964
Mr. William L. PhelanSr. VP & Chief Accounting OfficerN/AN/AN/A
Dr. Thomas J. KoobChief Scientific OfficerN/AN/A1949
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. The company's proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications; OrthoFlo, an amniotic fluid-derived allograft for homologous applications; Physio, a bone grafting material comprising 100% bone tissue with no added carrier; and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair. The company also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue; AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process; and AmnioFill, a cellular tissue matrix allograft that enhances healing. Its products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. The company sells its products through direct sales force, and independent stocking distributors, and third party representatives in the United States, as well as independent distributors internationally. MiMedx Group, Inc. is headquartered in Marietta, Georgia.

Corporate Governance

MiMedx Group, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.